Clinical Trial Update: BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

View source ↗

Summary

A prospective observational study of patients with Primary Hyperoxaluria Type 1 (PH1), sponsored by Alnylam, that is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria Type

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Primary Hyperoxaluria Type 1 | Status: ACTIVE_NOT_RECRUITING